Preliminary clinical trial shows great promise for new multiple sclerosis treatment
A study conducted by Dr. Rhonda Voskuhl, a UCLA neurologist, shows that combining estriol, a female hormone, with Copaxone, a medication currently used to treat multiple sclerosis, reduced the relapse rate of MS by nearly 50 percent with only one year of treatment.
Voskuhl presented the results of the preliminary Phase II clinical trial today at the annual meeting of the American Academy of Neurology in Philadelphia.
The randomized, double-blind, placebo-controlled trial involved 158 women with relapsing-remitting MS. At 16 sites across the U.S., one group of women was treated with Copaxone, a commonly prescribed...
Source: UCLA Newsroom: Health Sciences - April 30, 2014 Category: Universities & Medical Training Source Type: news
Estriol (Trimesta) and glatiramer acetate (Copaxone)
A phase II study of a combination of the female hormone and glatiramer acetate (Copaxone) found the combination reduced the relapse rate compare to glatiramer acetate and placebo. The effect in the second year there was still apparent but not statistically significant. Presented at the AAN conference.
Health Canal
Hormones - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 29, 2014 Category: Neurology Source Type: news
Preliminary results show improvement in MS symptoms
(NIH/National Institute of Neurological Disorders and Stroke) Combining the estrogen hormone estriol with Copaxone, a drug indicated for the treatment of patients with relapsing forms of multiple sclerosis, may improve symptoms in patients with the disorder, according to preliminary results from a clinical study of 158 patients with relapsing remitting multiple sclerosis. The findings were presented today by Rhonda Voskuhl, M.D., from the University of California, Los Angeles, at the American Academy of Neurology Annual Meeting in Philadelphia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 29, 2014 Category: Biology Source Type: news
US Patents rejects Teva's plea on Copaxone; Natco shares up
Hyderabad-based Natco markets Copaxone (Glatiramer Acetate) -- used in the treatment of relapsing-remitting multiple sclerosis -- in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 4, 2014 Category: Pharmaceuticals Source Type: news
Teva Reports That Court Will Hear Its Appeal On COPAXONE Patent
Teva Pharmaceutical Industries announced that the U.S. Supreme Court has granted its COPAXONE certiorari petition. The Court will hear the company’s appeal of a decision regarding the claim invalidation of the U.S. “808 Patent” for the drug. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 2, 2014 Category: Pharmaceuticals Source Type: news
Teva Appeals Patent Case of MS Drug Copaxone
Supreme Court to hear appeal from Teva regarding five of its patents for multiple sclerosis drug Copaxone (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 2, 2014 Category: Pharmaceuticals Source Type: news
Supreme Court to Hear Appeal of Generic Drug Case
The court’s decision could delay competitors’ generic versions of Copaxone, made by Teva Pharmaceutical Industries. (Source: NYT)
Source: NYT - April 1, 2014 Category: American Health Authors: By ANDREW POLLACK Tags: Inventions and Patents Drugs (Pharmaceuticals) Teva Pharmaceutical Industries Ltd TEVA NASDAQ Novartis AG NVS NYSE Momenta Pharmaceuticals Inc MNTA NASDAQ Multiple Sclerosis Supreme Court (US) Generic Brands and Products Mylan Inc MYL NASD Source Type: news
Supreme Court to Hear Appeal of Multiple Sclerosis Drug Case
The court’s decision could delay competitors’ generic versions of Copaxone, made by Teva Pharmaceutical Industries. (Source: NYT)
Source: NYT - March 31, 2014 Category: American Health Authors: By ANDREW POLLACK Tags: Inventions and Patents Drugs (Pharmaceuticals) Teva Pharmaceutical Industries Ltd TEVA NASDAQ Novartis AG NVS NYSE Momenta Pharmaceuticals Inc MNTA NASDAQ Multiple Sclerosis Supreme Court (US) Generic Brands and Products Mylan Inc MYL NASD Source Type: news
Teva Uses Grassroot Efforts to Retain Copaxone Customers; Insurers Remain Unconvinced
In the race to switch multiple sclerosis patients to a new, patent-protected version of its top selling drug, Copazone, Teva Pharmaceutical Industries is using records from its 24-hour support hotline in the U.S. to personally contact 85,000 patients. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 6, 2014 Category: Pharmaceuticals Source Type: news
U.S. Attorney Puts Teva's Marketing Of Drugs Under Scrutiny
Federal prosecutors in New York are investigating Teva’s sales and marketing practices for its drugs Copaxone and Azilect. Possible civil violations of the federal False Claims Act are being looked into, the company said. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 11, 2014 Category: Pharmaceuticals Source Type: news
Teva Reports Strong Q4 And 2013 Results
Teva Pharmaceuticals released robust fourth quarter and full year 2013 results this week. The company said its multiple sclerosis treatment Copaxone made record annual revenues. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 7, 2014 Category: Pharmaceuticals Source Type: news
FDA approves Copaxone 3 times a week for MS
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 5, 2014 Category: Journals (General) Source Type: news
FDA Approves Higher/Less Frequent Doses of Teva's Copaxone as Generics Hover
Teva Pharmaceutical Industries was granted U.S. FDA approval for a longer-acting version of its Copaxone multiple-sclerosis drug. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 30, 2014 Category: Pharmaceuticals Source Type: news
Teva's New Copaxone Formulation For MS Patients Approved By FDA
The U.S. Food and Drug Administration (FDA) has approved Teva’s supplemental new drug application (sNDA) for a new formulation for Copaxone. Copaxone is now available in 40mg/mL in a three-times-a-week dosage. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - January 29, 2014 Category: Pharmaceuticals Source Type: news
FDA Approves 3-Times-a-Week Copaxone in MSFDA Approves 3-Times-a-Week Copaxone in MS
On the basis of results of the GALA trial, the FDA has approved a higher-dose, lower-frequency regimen of glatiramer acetate, the company announced. FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 29, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
